Stock CYTOKINETICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Cytokinetics, Inc. Nasdaq

Equities

US23282W1009

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Cytokinetics, Inc.
06-24 JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating MT
06-17 Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing MT

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating
MT
Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing
MT
Cytokinetics Insider Sold Shares Worth $1,183,391, According to a Recent SEC Filing
MT
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
AQ
Cytokinetics Announces Initiation of Phase 1 Study of Aficamten in Healthy Japanese Participants
CI
Cytokinetics Insider Sold Shares Worth $413,106, According to a Recent SEC Filing
MT
Transcript : Cytokinetics, Incorporated Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 11:20 AM
Cytokinetics Insider Sold Shares Worth $1,099,125, According to a Recent SEC Filing
MT
Sector Update: Health Care Stocks Advance Late Afternoon
MT
Sector Update: Health Care Stocks Rise Wednesday Afternoon
MT
Sector Update: Health Care
MT
Cytokinetics Says Third Party Dropped Takeover Bid Despite Negotiations; Shares Rise
MT
Cytokinetics CEO Says Board Would Have Backed Actionable Buyout
DJ
Cytokinetics Incorporated : Regulation FD Presentation Form 8 K
PU
Cytokinetics Says Third Party Did Not Move Forward with Acquisition After Talks
CI
Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
AQ
B. Riley Cuts Price Target on Cytokinetics to $92 From $122, Maintains Buy Rating
MT
Cytokinetics Insider Sold Shares Worth $635,978, According to a Recent SEC Filing
MT
Cytokinetics to Participate in June Investor Conferences
AQ
Truist Securities Lowers Price Target on Cytokinetics to $70 From $86, Maintains Buy Rating
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CYTK Stock
  4. Stock
  5. News Cytokinetics, Inc.